ClinicalTrials.gg

Program

Memantine

Also written as “Memantine Hydrochloride (HCl)”, “memantine” and “memantine HCl”.

Its studies are mostly in Alzheimer Disease · Autistic Disorder · Autism Spectrum Disorder · Glaucoma, Open-Angle · Cancer Pain, led by 7 companies.

Furthest: phase 4, since Jun 6, 200627 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie130 open or runningphase 4since Jun 6, 2006Dec 1, 2004none ahead
H. Lundbeck60 open or runningphase 4since Mar 3, 2009Mar 3, 2009none ahead
Merz Pharma40 open or runningphase 4since Mar 27, 2008Feb 14, 2008none ahead
Carnot Laboratories10 open or runningphase 4since Feb 11, 2026Feb 11, 2026none ahead
Gedeon Richter Plc.10 open or runningphase 1since Nov 15, 2013Nov 15, 2013none ahead
Geropharm10 open or runningphase 1since Apr 18, 2017Apr 18, 2017none ahead
Mendel AI10 open or runningphase 3since Jan 30, 2021Jan 30, 2021none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 9 studies since Dec 1, 2004.

  1. Mar 27, 2008Phase 4 study in Alzheimer DiseaseMerz Pharma · NCT00649220 · 19 enrolled · Germany
  2. Dec 5, 2008Phase 3 study in Alzheimer DiseaseMerz Pharma · NCT00804271 · 487 enrolled · Germany
  3. Mar 3, 2009H. Lundbeck's first studies: 2 phase 4 studiesNew to H. LundbeckH. Lundbeck · NCT00855686, NCT00862940
  4. Mar 5, 20092 phase 3 studies in Alzheimer DiseaseH. Lundbeck · NCT00857649, NCT00857233
  5. Mar 30, 2009Phase 2 study in Autistic DisorderAbbVie · NCT00872898 · 124 enrolled · United States
  6. Dec 15, 2010Phase 2 study in Memory DisordersMerz Pharma · NCT01261741 · 299 enrolled · Germany, United Kingdom
  7. May 3, 20123 phase 2 studiesAbbVie · NCT01592786, NCT01592773, NCT01592747
  8. Nov 15, 2013Gedeon Richter Plc.'s first study: phase 1 study in ObesityNew to Gedeon Richter Plc.Gedeon Richter Plc. · NCT02001584 · United Kingdom
  9. Nov 26, 2013Phase 2 study in Autistic DisorderAbbVie · NCT01999894 · 102 enrolled · United States
  10. Sep 16, 2015Phase 4 study in Alzheimer DiseaseH. Lundbeck · NCT02553928 · 62 enrolled · China
  11. Apr 18, 2017Geropharm's first study: phase 1 study in Bioequivalence, AUC, Cmax, PharmacokineticsNew to GeropharmGeropharm · NCT03121820 · 18 enrolled · Russian Federation
  12. Sep 12, 2018Phase 1 study in HealthyH. Lundbeck · NCT03670095 · 64 enrolled · China
  13. Jan 30, 2021Mendel AI's first study: phase 3 study in Cancer PainNew to Mendel AIMendel AI · NCT04737967 · 60 enrolled · Egypt
  14. Feb 11, 2026Carnot Laboratories's first study: phase 4 study in Alzheimer DiseaseNew to Carnot LaboratoriesCarnot Laboratories · NCT07417670 · 105 enrolled · Mexico

TargetBeta

“Glutamate [NMDA] receptor negative allosteric modulator”ChEMBL 37, by rule

Other programs on the same 7 targets

ProgramCompanyFurthest phaseStudies
EsketamineruleJohnson & Johnsonphase 451

Studies

All 27 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07417670Alzheimer Disease · Mexico4CompletedCarnot LaboratoriesAug 12, 2025105
NCT04737967Cancer Pain · Egypt3UNKNOWNMendel AIAug 15, 202160
NCT03670095Healthy · China1CompletedH. LundbeckDec 24, 201864
NCT03121820Bioequivalence, AUC, Cmax, Pharmacokinetics · Russian Federation1CompletedGeropharmNov 19, 201618
NCT02553928Alzheimer Disease · China4CompletedH. LundbeckJul 201662
NCT01999894Autistic Disorder · United States2CompletedAbbVieFeb 2013102
NCT02001584Obesity · United Kingdom1CompletedGedeon Richter Plc.May 2014
NCT01592786Autism Spectrum Disorder · United States, Australia, Belgium and more2CompletedAbbVieJul 2013906
NCT01592773Autism Spectrum Disorder · United States, Belgium, Canada and more2TerminatedAbbVieJan 2014747
NCT01592747Autistic Disorder · United States, Belgium, Colombia and more2CompletedAbbVieSep 2013479
NCT01261741Memory Disorders · Germany, United Kingdom2CompletedMerz PharmaAug 2011299
NCT00872898Autistic Disorder · United States2CompletedAbbVieAug 2012124
NCT00862940Alzheimer Disease4CompletedH. LundbeckFeb 2009277
NCT00857649Alzheimer Disease · Canada3TerminatedH. LundbeckApr 2010369
NCT00857233Alzheimer Disease · Canada3TerminatedH. LundbeckJul 2010297
NCT00855686Lewy Body Disease · Germany4CompletedH. LundbeckDec 2008199
NCT00804271Alzheimer Disease · Germany3CompletedMerz PharmaNov 2009487
NCT00649220Alzheimer Disease · Germany4TerminatedMerz PharmaMay 200919
NCT00624026Alzheimer Disease · Germany3CompletedMerz PharmaDec 2008107
NCT00469456Alzheimer Disease · Australia, New Zealand, South Africa4CompletedAbbVieNov 2008265
NCT00334906Alzheimer Disease · United States4CompletedAbbVieNov 200775
NCT00322153Alzheimer Disease · United States, Argentina, Chile and more3CompletedAbbVieOct 2007677
NCT00168350Glaucoma, Open-Angle3CompletedAbbVieSep 20061,179
NCT00141882Glaucoma, Open-Angle3CompletedAbbVieJan 20061,119
NCT00106405Bipolar Disorder · United States2CompletedAbbVieNov 200535
NCT00097942Schizophrenia · United States2CompletedAbbVieSep 2005138
NCT00097916Alzheimer Disease · United States3CompletedAbbVieApr 200634

How it is read

Names in the registry

  • “Memantine”, 11 entries
  • “Memantine Hydrochloride (HCl)”, 4 entries
  • “memantine”, 3 entries
  • “memantine HCl”, 3 entries
  • “Memantine HCl”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.